Immunovant, Inc.

IMVT · NASDAQ
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income-$413,840-$259,336-$210,960-$156,730
Dep. & Amort.$377$231$193$126
Deferred Tax$0$0$0$0
Stock-Based Comp.$49,487$41,116$32,296$34,244
Change in WC-$12,031$2,632-$10,853$15,142
Other Non-Cash$133$1,130$1,131$1,106
Operating Cash Flow-$375,874-$214,227-$188,193-$106,112
Investing Activities
PP&E Inv.-$759-$360-$197-$254
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$759-$360-$197-$254
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$450,000$472,745$70,500$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$4,492-$318$385$200,129
Financing Cash Flow$454,492$472,427$70,885$200,129
Forex Effect$747$993$220-$92
Net Chg. in Cash$78,606$258,833-$117,285$93,671
Supplemental Information
Beg. Cash$635,365$376,532$493,817$400,146
End Cash$713,971$635,365$376,532$493,817
Free Cash Flow-$376,633-$214,587-$188,390-$106,366